Latest oncology resources and news surrounding Novartis data featured at European Society for Medical Oncology (ESMO)
Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond, a first in the healthcare industry.
Alice Shaw, Global Head of Translational Clinical Oncology at Novartis, applies lessons from running clinical trials to the work of designing them.
Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.
This site is intended for a global audience.